Sander Slootweg


Sander is Managing Partner of Forbion Capital Partners and co-founded ABN AMRO Capital Life Sciences in 2000 and Forbion Capital Partners in 2006. He currently serves on the boards of Forbion’s portfolio companies Xention Discovery Ltd, Ario Pharma Ltd, Pulmagen Therapeutics, Ltd and Oxyrane Ltd. In addition, Sander was responsible for two of Forbion’s more recent exits: Dezima Pharma B.V. was sold to Amgen in September of 2015 for up to USD 1.55 billion plus royalties and Biovex, Inc. was sold to Amgen in March of 2011 for up to USD 1 billion. In recent years Sander has served on the boards of uniQure N.V. (QURE), Fovea Pharmaceutics S.A.(Sold to Sanofi in 2009), Argenta Discovery Ltd (sold to Galapagos in 2010), Alantos Pharmaceuticals, Inc. (sold to Amgen in 2007), Impella Cardiosystems AG (sold to Abiomed, Inc. in 2005), Glycart AG (sold to Roche in 2005), Cambridge Drug Discovery Ltd (sold to Biofocus Plc in 2001), Pieris AG (PIRS) and has acted as the Chairman of the Board of AMT NV (Amsterdam, Netherlands / Euronext: AMT). Before co-founding Forbion Capital Partners, he was an Investment Director at ABN AMRO Capital Life Sciences. His other activities at ABN AMRO included buy-out/ growth equities at ABN AMRO Capital, Equity Capital Markets Syndications (HQ Amsterdam) and Financial Institutions Relationship Management Latin America (Regional Office Miami). Sander holds degrees in Business and Financial Economics from the Free University of Amsterdam and Business Administration from Nijenrode University, The Netherlands.